Antiplatelets
High-yield Verified · Oct 2026Each drug cuts one link in the platelet’s amplification loop — thromboxane A₂ (aspirin), ADP at P2Y12, the final GP IIb/IIIa bridge, or the platelet’s cAMP brake — and whether it lets go decides how long its effect outlasts the last dose.
Nursing view → administration, monitoring and patient teaching
Compare: Antithrombotics compared — anticoagulants, antiplatelets and thrombolytics →
Drugs
Mechanism
Aspirin irreversibly inhibits platelet COX-1, reducing thromboxane A₂. Clopidogrel, prasugrel, ticagrelor and IV cangrelor block the platelet P2Y12 (ADP) receptor — clopidogrel/prasugrel as liver-activated prodrugs, ticagrelor and cangrelor directly and reversibly. Eptifibatide and tirofiban reversibly block the glycoprotein IIb/IIIa receptor, preventing fibrinogen and von Willebrand factor binding. Cilostazol inhibits phosphodiesterase III, and dipyridamole inhibits adenosine uptake; both raise platelet cAMP. All reduce platelet aggregation.
From injury to aggregate: the platelet pathway
When the endothelium breaks, platelets meet exposed collagen, ADP, thrombin and thromboxane A₂, and adhesion is mediated in part by von Willebrand factor binding platelet GP Ib-IX. Adherent platelets release granule contents — including ADP and thromboxane A₂ (TxA₂) — which activate neighbouring platelets: an amplification loop. Intact endothelium releases prostacyclin (PGI₂), which keeps circulating platelets quiet; the balance between prostacyclin and TxA₂ sets how much plug forms.
TxA₂ is made from membrane arachidonic acid: COX-1 (constitutive in platelets) forms PGH₂, and TxA₂ synthase converts it to TxA₂. With a half-life of about 30 seconds it acts locally, through the Gq-coupled TP receptor: phospholipase C, IP₃ and DAG raise calcium and activate protein kinase C. That "inside-out" signal changes GP IIb/IIIa to its active form, and fibrinogen and von Willebrand factor then bridge platelet to platelet — the final common step of aggregation that every activator converges on.
Irreversible versus reversible — how long the effect outlasts the drug
Aspirin acetylates and irreversibly inhibits COX-1. Platelets have no nucleus and cannot make new enzyme, so TxA₂ synthesis stays suppressed for the rest of each platelet’s life — about 7 to 10 days — even though aspirin itself is hydrolysed within hours. Antiplatelet doses give about 90% COX inhibition, whereas inhibiting endothelial prostacyclin takes higher doses. Unlike aspirin, ibuprofen and naproxen block COX-1 reversibly.
The active metabolites of clopidogrel and prasugrel bind P2Y12 irreversibly, so their effect also lasts the platelet’s lifespan; platelet aggregation recovers as new platelets enter the circulation (about 5 days after stopping clopidogrel). Ticagrelor and its active metabolite interact with P2Y12 reversibly, and cangrelor binds reversibly with a half-life of minutes — its effect is gone about an hour after the infusion stops. Eptifibatide and tirofiban dissociate from GP IIb/IIIa, so platelet function returns within hours, and cilostazol’s inhibition is reversible too.
Prodrugs and CYP2C19
Clopidogrel is a prodrug with two competing fates. About 85% is hydrolysed by esterases to an inactive carboxylic acid. The rest is oxidised by cytochrome P450 enzymes to 2-oxo-clopidogrel and then to the active thiol metabolite — and CYP2C19 takes part in both steps. CYP2C19 poor metabolizers (homozygous for non-functional alleles; about 2% of White and 4% of Black patients, more in Asian patients) form less active metabolite and get less platelet inhibition — the reason for clopidogrel’s boxed warning. Omeprazole and esomeprazole inhibit CYP2C19 and significantly reduce clopidogrel’s effect.
Prasugrel is also a prodrug, but it is hydrolysed in the intestine to a thiolactone and then activated in a single CYP step, mainly by CYP3A4 and CYP2B6; genetic variation in CYP2C19, CYP2C9, CYP3A5 or CYP2B6 has no relevant effect on its active metabolite. Ticagrelor does not depend on that pathway: in a genetic substudy of its outcome trial, its benefit did not depend on CYP2C19 loss-of-function status. Cangrelor needs no metabolic activation at all.
The cAMP brake: cilostazol and dipyridamole
Raising platelet cAMP opposes activation. Cilostazol (with several active metabolites) inhibits phosphodiesterase III, so cAMP accumulates in platelets — reversibly inhibiting aggregation to many stimuli — and in blood vessels, where it causes vasodilation, more in the femoral bed than elsewhere. Dipyridamole blocks adenosine uptake into platelets, endothelium and red cells; the extra adenosine acts on the platelet A₂ receptor, stimulates adenylate cyclase and raises cAMP. It also inhibits cGMP phosphodiesterase, augmenting nitric-oxide–driven cGMP.
The same balance explains a cardiovascular warning outside this class: selective COX-2 inhibitors can cause cardiotoxicity, plausibly because they suppress endothelial prostacyclin while platelet COX-1 keeps making TxA₂.
Comparing the drugs
Antiplatelet agents at a glance
| Drug | Target | Reversible? | Activation | Effect after stopping |
|---|---|---|---|---|
| Aspirin | COX-1 (↓ TxA₂) | No — acetylation | Active (hydrolysed to salicylate) | Platelet lifespan, about 7–10 days |
| Clopidogrel | P2Y12 | No | Prodrug — CYP2C19 in both oxidation steps | Recovers in about 5 days as new platelets appear |
| Prasugrel | P2Y12 | No | Prodrug — gut thiolactone, one CYP step (3A4, 2B6) | Platelet lifespan; label: stop ≥ 7 days before surgery |
| Ticagrelor | P2Y12 | Yes | Active as given (CYP3A4 makes an active metabolite) | Half-lives about 7 h (drug) and 9 h (metabolite) |
| Cangrelor (IV) | P2Y12 | Yes | None — dephosphorylated in plasma | No antiplatelet effect after about 1 hour |
| Eptifibatide (IV) | GP IIb/IIIa | Yes | None (cyclic peptide) | Platelet function normal in about 4–8 h |
| Tirofiban (IV) | GP IIb/IIIa | Yes | None | Half-life about 2 h; cleared mainly by the kidneys |
| Cilostazol | PDE III (↑ cAMP) | Yes | Active, plus active metabolites (CYP3A4, CYP2C19) | Aggregation back to baseline by about 96 h |
| Dipyridamole | Adenosine uptake (↑ cAMP) | Yes | Active | Terminal half-life about 10 h |
Route, setting and signature hazard
| Drug | Route | Typical setting | Signature hazard |
|---|---|---|---|
| Aspirin | Oral | Secondary prevention; DAPT backbone | GI irritation and bleeding; AERD; Reye syndrome in children |
| Clopidogrel | Oral | DAPT, stroke/PAD | Reduced effect in CYP2C19 poor metabolizers (boxed) |
| Prasugrel | Oral | ACS managed with PCI | Bleeding (boxed); contraindicated after stroke/TIA |
| Ticagrelor | Oral | ACS | Bleeding (boxed); dyspnea; ventricular pauses |
| Cangrelor | IV | PCI in P2Y12-naive patients | Bleeding; timing of the oral switch |
| Eptifibatide · tirofiban | IV | NSTE-ACS / PCI | Access-site bleeding; acute profound thrombocytopenia |
| Cilostazol | Oral | Intermittent claudication | Contraindicated in any heart failure (boxed) |
| Dipyridamole | Oral | With warfarin after valve replacement; with aspirin after stroke | Vasodilation — headache, dizziness, worse angina |
Pharmacokinetics
- Aspirin — aspirin
- Absorbed mainly in the stomach and hydrolysed in plasma to salicylic acid. Salicylate elimination is first-order at low doses but saturates at higher levels and becomes zero-order, so concentrations rise steeply with high or repeated doses. Alkalinising the urine increases renal salicylate clearance.
- Clopidogrel — clopidogrel
- Half-life about 6 hours, with the active metabolite lasting only about 30 minutes; only about 15% of a dose becomes active. Because the active metabolite is short-lived, transfused platelets can restore hemostasis — though less effectively within hours of a dose.
- Prasugrel — prasugrel
- Rapidly converted to its active metabolite (half-life about 7 hours, range 2–15). Strong CYP inducers such as rifampicin did not significantly change active-metabolite exposure or platelet inhibition.
- Ticagrelor — ticagrelor
- Oral bioavailability about 36%. CYP3A4 metabolises it and forms its major active metabolite, so strong CYP3A inhibitors raise exposure (more bleeding and dyspnea) and strong inducers lower it. Elimination is mainly hepatic, with the metabolite cleared largely in bile.
- Cangrelor — cangrelor
- Peak within 2 minutes of the IV bolus; deactivated in the circulation by dephosphorylation, independent of the liver and of renal or hepatic function; half-life about 3–6 minutes.
- GP IIb/IIIa inhibitors — eptifibatide, tirofiban
- Eptifibatide: half-life about 2.5 hours, about 25% protein-bound, renal clearance about 50% of the total — clearance halves and levels double when creatinine clearance is below 50 mL/min. Tirofiban: half-life about 2 hours, about 65% excreted in urine largely unchanged, removed by hemodialysis.
- Cilostazol and dipyridamole — cilostazol, dipyridamole
- Cilostazol is metabolised mainly by CYP3A4 (less by CYP2C19) to active metabolites — one supplies at least half the activity — with half-lives of about 11–13 hours; a high-fat meal raises peak levels about 90%. Dipyridamole peaks at about 75 minutes, has a terminal half-life of about 10 hours, is highly protein-bound and is glucuronidated in the liver and excreted in bile.
Pharmacogenomics
Uses & drug choice
- Acute coronary syndrome and secondary prevention after MI
- Coronary stents — dual antiplatelet therapy (aspirin + a P2Y12 inhibitor)
- Ischemic (non-cardioembolic) stroke / TIA and peripheral arterial disease
- Eptifibatide or tirofiban IV during PCI or for non-ST-elevation ACS (GP IIb/IIIa)
- Cangrelor IV during PCI in patients not yet on a P2Y12 inhibitor
- Cilostazol for intermittent claudication — increases walking distance
- Dipyridamole with warfarin after prosthetic heart-valve replacement; combined with aspirin to reduce stroke after TIA or ischemic stroke
Adverse effects
- Bleeding (all agents)
- Blocking TxA₂, ADP signalling or the GP IIb/IIIa bridge prevents the platelet plug that is the first step of hemostasis; with the irreversible agents the defect lasts until new platelets are made.
- Aspirin: GI irritation and bleeding
- Gastrointestinal irritation, from gastritis to bleeding, is aspirin’s most common adverse effect; the platelet defect adds to bleeding from any mucosal injury, and combining it with anticoagulants increases bleeding further.
- Aspirin-exacerbated respiratory disease
- Blocking COX is thought to shunt arachidonic acid toward the lipoxygenase pathway, increasing leukotrienes — bronchospasm and nasal symptoms in susceptible patients.
- Ticagrelor: dyspnea
- Usually mild to moderate and self-limiting; pulmonary function testing in a PLATO substudy found no adverse effect on lung function.
- Ticagrelor: ventricular pauses and bradyarrhythmias
- More ventricular pauses occurred with ticagrelor in a Holter substudy, and patients with conduction disease without a pacemaker may be at higher risk.
- GP IIb/IIIa inhibitors: acute thrombocytopenia
- Can be immune-mediated (drug-dependent antibodies) or non-immune; platelet counts usually recover after the drug is stopped.
- Cilostazol: tachycardia and harm in heart failure
- PDE III inhibition raises cardiac cAMP: heart rate rises in patients (about 5–7 bpm), and in animal studies contractility and ventricular automaticity rose too. Drugs with this effect have decreased survival in class III–IV heart failure.
- Dipyridamole: headache, dizziness, worse angina
- It is a vasodilator. Acute IV dipyridamole can worsen perfusion distal to a partial coronary occlusion — the coronary steal used to provoke ischemia in pharmacologic stress testing.
Toxicity & antidote
Aspirin overdose is a metabolic emergency: direct stimulation of the respiratory centre causes respiratory alkalosis, while salicylic acid and lactate (from uncoupled oxidative phosphorylation) cause a high-anion-gap metabolic acidosis; tinnitus, vomiting, hyperthermia, seizures and pulmonary edema can follow. Acidemia shifts salicylate into its non-ionised, CNS-penetrating form, so treatment keeps the blood and urine alkaline (bicarbonate, watching potassium) and uses hemodialysis for severe cases.
The other agents have no specific antidote. Because the active metabolites of clopidogrel and prasugrel are short-lived, transfused platelets can restore hemostasis, though less effectively within hours of a dose. The IV agents are simply stopped — cangrelor wears off within an hour, eptifibatide and tirofiban within hours, and tirofiban is dialysable. Dipyridamole overdose causes flushing, hypotension and tachycardia; a xanthine such as aminophylline may reverse its hemodynamic effects.
Interactions
Contraindications
- Active pathologic bleeding (e.g. peptic ulcer, intracranial hemorrhage) — Antiplatelet therapy would worsen an ongoing bleed the body is already struggling to control.
- History of intracranial hemorrhage (ticagrelor, prasugrel) — The high risk of a repeat brain bleed is unacceptable with these potent agents.
- Cilostazol with heart failure of any severity — Boxed contraindication: cilostazol is a phosphodiesterase III inhibitor, and drugs with this effect have decreased survival in class III–IV heart failure.
- Prior stroke/TIA (prasugrel) — Prasugrel markedly increases intracranial bleeding risk in patients with prior stroke/TIA — it is contraindicated there.
- Eptifibatide: bleeding diathesis or bleeding within 30 days, severe uncontrolled hypertension (> 200/110), major surgery within 6 weeks, stroke within 30 days or any hemorrhagic stroke, another IV GP IIb/IIIa inhibitor, or dialysis dependence — Labeled contraindications for eptifibatide. It is cleared partly by the kidneys, and blocking the final step of aggregation makes any recent bleed, surgery or stroke dangerous.
- Tirofiban: active internal bleeding, bleeding diathesis, major surgery or severe trauma within the past month, or thrombocytopenia after previous tirofiban — Labeled contraindications for tirofiban: bleeding is its most common complication, and profound thrombocytopenia has occurred with it.
- Hypersensitivity to the drug (e.g., aspirin allergy) — Each label lists hypersensitivity (e.g., anaphylaxis) to the drug as a contraindication; aspirin labels say do not use if allergic to aspirin. With clopidogrel, rash, angioedema or blood reactions have occurred, including in patients who reacted to another thienopyridine before.
- Aspirin in children and teenagers who have, or are recovering from, chickenpox or flu-like symptoms — Aspirin labels say they should not use it because of Reye’s syndrome, a rare but serious illness; new behavior changes with nausea and vomiting can be an early sign.
- Severe hepatic impairment (ticagrelor); aspirin-exacerbated respiratory disease use caution — Ticagrelor is hepatically handled; aspirin can trigger bronchospasm in aspirin-exacerbated respiratory disease.
High-yield
- A — aspirin acetylates COX-1 irreversibly
- C — clopidogrel’s active metabolite binds P2Y12 irreversibly
- P — prasugrel’s active metabolite binds P2Y12 irreversibly
- Each lasts the platelet’s life (about 7–10 days); ticagrelor, cangrelor, the GP IIb/IIIa blockers and cilostazol let go
- Can’t — 85% is wasted by esterases; CYP2C19 is needed in both oxidation steps to the active thiol
- Cope — poor metabolizers get less platelet inhibition (boxed warning)
- Without — omeprazole and esomeprazole inhibit CYP2C19 and blunt it
- CYP2C19-independent alternatives — prasugrel or ticagrelor (CPIC)
Practice questions
Q1A 66-year-old man taking low-dose aspirin for secondary prevention is scheduled for elective surgery with a high bleeding risk. The surgeon asks why the aspirin must be stopped about a week in advance when its plasma half-life is so short.
Which feature of aspirin best explains this?
- A.It is renally cleared with zero-order kinetics at low doses
- B.It reversibly inhibits COX-1 in endothelial cells
- C.It blocks the GP IIb/IIIa receptor for the platelet’s lifespan
- D.It is a prodrug activated by CYP2C19
- E.It irreversibly acetylates COX-1 in platelets, which cannot make new enzyme
Show answer
E. It irreversibly acetylates COX-1 in platelets, which cannot make new enzyme — Aspirin irreversibly inhibits platelet COX-1. Platelets cannot synthesise new COX, so thromboxane A₂ production stays suppressed for the platelet’s lifespan — about 7 to 10 days — long after the drug has been hydrolysed. Salicylate elimination is first-order at low doses.
Q2A 58-year-old man of East Asian ancestry has stent thrombosis 3 weeks after PCI despite reliably taking aspirin and clopidogrel. Genotyping shows two non-functional CYP2C19 alleles.
What best explains the treatment failure?
- A.Accelerated esterase hydrolysis of aspirin
- B.Reversible binding of clopidogrel’s active metabolite, so inhibition fades between doses
- C.Reduced conversion of clopidogrel to its active thiol metabolite
- D.Increased platelet COX-2 expression
- E.Rapid renal excretion of unchanged clopidogrel
Show answer
C. Reduced conversion of clopidogrel to its active thiol metabolite — Clopidogrel is a prodrug; CYP2C19 participates in both oxidative steps to the active thiol metabolite. Poor metabolizers — more common in Asian patients — form less active metabolite and have less platelet inhibition, the subject of the boxed warning. CPIC recommends avoiding clopidogrel in poor metabolizers and using prasugrel or ticagrelor if not contraindicated. Aspirin is hydrolysed in plasma in everyone, but its COX-1 inhibition is irreversible, so that does not matter; COX-2 is found in only a small fraction of circulating platelets; clopidogrel’s active metabolite binds P2Y12 irreversibly, so its effect does not fade between doses; and clopidogrel is extensively metabolized — mostly by esterases to an inactive acid — rather than excreted unchanged.
Q3During urgent PCI, a P2Y12-naive patient receives an IV P2Y12 inhibitor bolus and infusion. Halfway through the infusion, a clopidogrel loading dose is given. Platelet testing after the infusion stops shows little inhibition.
Why was the clopidogrel ineffective?
- A.Cangrelor needs hepatic activation that competes with clopidogrel’s
- B.Clopidogrel requires renal activation
- C.The IV drug is a GP IIb/IIIa antagonist that blocks oral absorption
- D.Clopidogrel’s short-lived active metabolite could not bind P2Y12 while cangrelor occupied it
- E.Cangrelor is dephosphorylated into a clopidogrel antagonist
Show answer
D. Clopidogrel’s short-lived active metabolite could not bind P2Y12 while cangrelor occupied it — Clopidogrel or prasugrel given during a cangrelor infusion has no antiplatelet effect until the next dose, because cangrelor occupies P2Y12 while the thienopyridine’s short-lived active metabolite is present. They are given after the infusion stops; ticagrelor can be given during it. Cangrelor itself needs no metabolic activation and its pharmacokinetics do not depend on hepatic function; it is dephosphorylated to a nucleoside with negligible antiplatelet activity, not to an antagonist; and clopidogrel is activated by the cytochrome P450 system, not by the kidney.
Q4A 71-year-old woman with intermittent claudication asks about a drug to walk farther. She has heart failure with reduced ejection fraction, NYHA class II.
Why is cilostazol contraindicated for her?
- A.As a PDE III inhibitor, it belongs to a drug group that has decreased survival in heart failure
- B.It slows the heart rate, worsening heart failure
- C.It is cleared unchanged by the kidneys
- D.It irreversibly blocks P2Y12
- E.It is a prodrug that needs CYP2C19 activation
Show answer
A. As a PDE III inhibitor, it belongs to a drug group that has decreased survival in heart failure — Cilostazol and several of its metabolites inhibit phosphodiesterase III. Several drugs with this effect have decreased survival in class III–IV heart failure, so cilostazol carries a boxed contraindication in heart failure of any severity. It is metabolised by CYP3A4 and CYP2C19, not cleared unchanged. Cilostazol itself is active — it and several metabolites inhibit PDE III, raising cAMP and reversibly inhibiting aggregation — so it is not a prodrug, and irreversible P2Y12 blockade belongs to clopidogrel and prasugrel. It raises the heart rate by about 5–7 beats per minute rather than slowing it.
Q5A 62-year-old man with NSTE-ACS starts an IV antiplatelet infusion together with heparin. Six hours later his platelet count, 240,000/mm³ at baseline, is 38,000/mm³; a citrate sample confirms the result.
What is the most appropriate next step?
- A.Continue both drugs and transfuse platelets
- B.Stop both the GP IIb/IIIa inhibitor and heparin, and monitor platelet counts
- C.Switch heparin to warfarin
- D.Increase the infusion rate to overcome resistance
- E.Add aspirin
Show answer
B. Stop both the GP IIb/IIIa inhibitor and heparin, and monitor platelet counts — GP IIb/IIIa inhibitors can cause acute, profound thrombocytopenia, immune-mediated or not. Once thrombocytopenia is confirmed (and pseudothrombocytopenia excluded), both the GP IIb/IIIa inhibitor and heparin are stopped and platelet counts are followed; counts usually recover after the drug is stopped. Every other choice keeps the GP IIb/IIIa infusion running — transfusing over it, replacing only the heparin, increasing the rate or adding aspirin — when the label calls for stopping it.
Sources
- BRILINTA (ticagrelor) — boxed warnings (bleeding; aspirin > 100 mg reduces efficacy), FDA label — FDA / DailyMed
- Antiplatelet Medications — mechanisms, DAPT, adverse effects & contraindications — StatPearls (NCBI)
- Aspirin — COX-1 mechanism, 7–10-day platelet effect, GI & bleeding risk — StatPearls (NCBI)
- Open RN Nursing Pharmacology — Ch. 6 (antiplatelet grid: give with food, bleeding, 7–10 days) — Open RN (NCBI Bookshelf)
- Clopidogrel — CYP2C19 activation, poor-metabolizer boxed warning — StatPearls (NCBI)
- PLAVIX (clopidogrel) — boxed warning (CYP2C19), contraindications, PPIs — DailyMed (NLM)
- EFFIENT (prasugrel) — boxed warning (bleeding), contraindications — DailyMed (NLM)
- Bayer Aspirin Regimen (aspirin) — drug facts — DailyMed (NLM)
- ECOTRIN (aspirin) — drug facts (stomach bleeding, allergy alert) — DailyMed (NLM)
- Thrombosis — arterial vs venous thrombosis — StatPearls (NCBI)
- Intracranial Hemorrhage Overview — presenting signs — StatPearls (NCBI)
- StatPearls: Hypercoagulability — StatPearls (NCBI)
- StatPearls: Anterior Myocardial Infarction — StatPearls (NCBI)
- StatPearls: Virchow Triad — StatPearls (NCBI)
- StatPearls: Angioplasty — StatPearls (NCBI)
- StatPearls: Stent Thrombosis — StatPearls (NCBI)
- StatPearls: Cardiac Risk Assessment — StatPearls (NCBI)
- Eptifibatide injection (Baxter) — FDA label: GP IIb/IIIa mechanism, contraindications, bleeding, thrombocytopenia — FDA / DailyMed
- Eptifibatide — pharmacokinetics, thrombocytopenia, monitoring — StatPearls (NCBI)
- Glycoprotein IIb/IIIa Inhibitors — mechanism, IV-only agents — StatPearls (NCBI)
- Aggrastat (tirofiban) — FDA label: contraindications, thrombocytopenia monitoring, renal clearance — FDA / DailyMed
- Kengreal (cangrelor) — FDA label: reversible IV P2Y12 block, transition to oral P2Y12 inhibitors — FDA / DailyMed
- Cangrelor — no metabolic activation, monitoring — StatPearls (NCBI)
- Cilostazol tablets (Apotex) — FDA label: boxed heart-failure contraindication, PDE III mechanism, interactions — FDA / DailyMed
- Cilostazol — monitoring for blood dyscrasia — StatPearls (NCBI)
- Dipyridamole tablets (Amneal) — FDA label: adenosine mechanism, valve-replacement indication, stress-test hold — FDA / DailyMed
- Aspirin and extended-release dipyridamole (Amneal) — FDA label: stroke prevention, headache, bleeding — FDA / DailyMed
- Dipyridamole — mechanism and pharmacokinetics — StatPearls (NCBI)
- The use of stems in the selection of INN (2018) — -grel, -fiban, -tide — World Health Organization
- Physiology, Thromboxane A2 — COX-1, TP receptor, GP IIb/IIIa activation — StatPearls (NCBI)
- Physiology, Hemostasis — adhesion, activation, prostacyclin–thromboxane balance — StatPearls (NCBI)
- Prasugrel — mechanism and use — StatPearls (NCBI)
- CPIC guideline: CYP2C19 and clopidogrel — recommendations by phenotype (CPIC API) — CPIC
- Table of Pharmacogenomic Biomarkers in Drug Labeling — U.S. FDA
By LearnDrugs
Educational summary for medical students. Always verify against current prescribing information and guidelines. Not medical advice.